BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zai Lab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Zai Lab's drugs run\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06585787-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 585787)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate KarXT as a Treatment for Psychosis As
 sociated With Alzheimer's Disease (ADEPT-4)\nEstimated primary completion:
  24 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/xa
 nomeline-trospium-chloride#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06585787
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03981796-2052@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:Niraparib: Phase 3 readout est. (NCT03981796)
DESCRIPTION:Niraparib\, phase 3.\nStudy: A Study to Evaluate Dostarlimab Pl
 us Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Pa
 rticipants With Recurrent or Primary Advanced Endometrial Cancer\nEstimate
 d primary completion: 26 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/niraparib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03981796
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126224-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 126224)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Assess Efficacy and Safety of KarXT for the Tr
 eatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)\nEstima
 ted primary completion: 9 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06126224
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04641247-2052@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Niraparib: Phase 2 readout est. (NCT04641247)
DESCRIPTION:Niraparib\, phase 2.\nStudy: A Long-term Treatment Extension St
 udy of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TES
 ARO-sponsored Niraparib Study\nEstimated primary completion: 28 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04641247
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06140836-2264@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:Repotrectinib: Phase 3 readout est. (NCT06140836)
DESCRIPTION:Repotrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Repotrectinib Versus Crizotinib in Participants With Locally Adv
 anced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive N
 on-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)\nEstimated primary completio
 n: 16 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 repotrectinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06140836
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140913-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 140913)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Bipolar Diso
 rder.\nStudy: A Study to Evaluate the Efficacy and Safety of Adjunctive Ka
 rXT for the Treatment of Mania\, With or Without Mixed Features\, in Parti
 cipants With Bipolar-I Disorder Taking Lithium\, Valproate\, or Lamotrigin
 e\nEstimated primary completion: 28 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07140913
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980949-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20270907
DTEND;VALUE=DATE:20270908
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT05
 980949)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: Open-Label Extension Study to Assess the Long-Term Safety
  and Tolerability of KarXT in Subjects With Psychosis Associated With Alzh
 eimer's Disease (ADEPT-3)\nEstimated primary completion: 7 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-
 chloride#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05980949
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947941-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20280221
DTEND;VALUE=DATE:20280222
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 947941)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate Safety and Efficacy of KarXT + KarX-E
 C as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-
 5)\nEstimated primary completion: 21 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06947941
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03093116-2264@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Repotrectinib: Phase 1/2 readout est. (NCT03093116)
DESCRIPTION:Repotrectinib\, phase 1/2\, Solid Tumors.\nStudy: A Study of Re
 potrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring AL
 K\, ROS1\, or NTRK1-3 Rearrangements\nEstimated primary completion: 29 Feb
 ruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/repotrect
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03093116
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929273-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20280613
DTEND;VALUE=DATE:20280614
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 929273)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Bipolar Diso
 rder.\nStudy: A Study to Assess the Long-term Safety of KarXT for the Trea
 tment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)\nEstimated primar
 y completion: 13 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06929273
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976203-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 976203)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT + Ka
 rX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)\nEstimat
 ed primary completion: 11 September 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06976203
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976216-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 976216)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT + Ka
 rX-EC for Cognitive Impairment in Alzheimer's Disease\nEstimated primary c
 ompletion: 11 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06976216
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882785-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20280923
DTEND;VALUE=DATE:20280924
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 882785)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT in Acutely
  Psychotic Japanese Adult Participants With Schizophrenia\nEstimated prima
 ry completion: 23 September 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06882785
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011745-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20281103
DTEND;VALUE=DATE:20281104
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 011745)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Phase 3 Study to Evaluate the Safety and Efficacy of Ka
 rXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's D
 isease\nEstimated primary completion: 3 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07011745
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011732-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 011732)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Phase 3 Study to Evaluate the Safety and Efficacy of Ka
 rXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's D
 isease (ADAGIO-1)\nEstimated primary completion: 24 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-chloride
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 11732
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686263-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20290303
DTEND;VALUE=DATE:20290304
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 686263)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: Relapse Prevention Trial Evaluating KarXT Treatment in Schizoph
 renia\nEstimated primary completion: 3 March 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07686263
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937229-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 937229)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Long-term Efficacy and Safety of 
 KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)\nEstimated
  primary completion: 22 June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06937229
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284745-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20290806
DTEND;VALUE=DATE:20290807
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 284745)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3.\nStudy: A Stu
 dy of KarXT + KarX-EC for Treatment of Irritability in Children and Adoles
 cents With Autism\nEstimated primary completion: 6 August 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-chloride#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072847
 45
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285798-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20290806
DTEND;VALUE=DATE:20290807
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 285798)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3.\nStudy: A Stu
 dy of KarXT + KarX-EC for Treatment of Irritability in Children and Adoles
 cents With Autism Spectrum Disorder\nEstimated primary completion: 6 Augus
 t 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-tr
 ospium-chloride#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07285798
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288567-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 288567)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT for the Tr
 eatment of Schizophrenia in Adolescents (EMERGENT TEEN)\nEstimated primary
  completion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07288567
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424404-712@assetmemo.bio
DTSTAMP:20261121T004005Z
DTSTART;VALUE=DATE:20300308
DTEND;VALUE=DATE:20300309
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 424404)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Long-term Safety and Tolerability of Xa
 nomeline and Trospium Chloride for the Treatment of Psychiatric Disorders 
 in Children and Adolescents\nEstimated primary completion: 8 March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-ch
 loride#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07424404
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
